Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Abilify

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Abilify was produced by Otsuka and Bristol-Myers Squibb.

Lundbeck and Otsuka's Rexulti set for August launch in US

Lundbeck and Otsuka's Rexulti set for August launch in US Rexulti (brexpiprazole) is a dopamine D2 and serotonin 5-HT1A partial agonist positioned as a successor to the Otsuka's big-selling atypical antipsychotic Abilify (aripiprazole), which is sold by ... Abilify's primary use is in schizophrenia and bipolar

Ten new medicines recommended in Europe

Ten new medicines recommended in Europe This is a copycat version of Bristol-Myers Squibb/Otsuka's blockbuster Abilify (aripiprazole), which made $5.5bn last year, but is now starting to succumb to generic erosion.

Pfizer maintains lead in top CNS drug sales - just

Pfizer maintains lead in top CNS drug sales - just Otsuka's anti-psychotic drug Abilify (aripiprazole), which the company co-markets with Bristol-Myers Squibb, was once the sales leader in the CNS arena but it is now being hit

Schultz takes Lundbeck helm after leaving Novo Nordisk

Schultz takes Lundbeck helm after leaving Novo Nordisk Some of the central nervous system (CNS) drug developer's newer products showed encouraging signs in the first quarter, with sales of depot schizophrenia drug Abilify Maintena (aripiprazole) almost quadrupling to

BMS shines in Q1, but Abilify generics cast a long shadow

BMS shines in Q1, but Abilify generics cast a long shadow Bristol-Myers Squibb (BMS) posted a buoyant set of results in the first quarter, although the approval of generics to $8bn blockbuster Abilify in the US muted celebrations. ... BMS earns royalties on Abilify sales and the company reported revenues of

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS Just::

HAVAS Just:: is a different kind of healthcare communications agency. Our mission is to create campaigns that make people think....

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics